R.I. GABIDULLINA¹, F.R. NUHBALA¹, G.A. SMIRNOVA, E.V. VALEEVA¹, G.KH. GARIPOVA²

 ¹Kazan State Medical University, Kazan

²City Clinical Hospital № 7, Kazan

 Contact details:

Gabidullina R.I. — MD, Professor of the Department of Obstetrics and Gynecology named after V.S. Gruzdev

Address: 49 Butlerov St., Russian Federation, Kazan, 420012, tel.: +7-917-28-99-310, e-mail: ru.gabidullina@yandex.ru

The purpose — to estimate the prevalence of rs2498796 polymorphism of the АКТ1 gene and reveal its association with the risk of endometrial hyperplasia.

Material and methods. The study included 180 residents of the Republic of Tatarstan: 79 patients with endometrial hyperplasia, 101 women without endometrial pathology. Determination of rs2498796 polymorphism of the АКТ1 gene was carried out by the method of real time polymerase chain reaction. The study performed a χ2 test and evaluated the odds ratio.

Results. The ratio of homozygous for the allele C (C/C), heterozygous (C/T) and homozygous for the allele T (T/T) rs2498796 of the AKT1 gene was in the main group 35 (44,3%), 30 (38%), and 14 (17,7%), in the control group – 46 (45,5%), 45 (44,6%), and 10 (9,9%) respectively. The frequency of the T allele and the C allele rs2498796 in women with endometrial polyps was comparable to that in the control group (χ2=0,81, р=0,37).

Conclusion. Among 180 females of the Republic of Tatarstan included into the study, the associations of rs2498796 polymorphism of the АКТ1 gene with the risk of endometrial hyperplasia were not identified.

Key words: endometrial hyperplasia, endometrial cancer, polymorphism.

REFERENCES

1. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, vol. 68 (6), pp. 394–424.
2. Lortet-Tieulent J., Ferlay J., Bray F., Jemal A. International patterns and trends in endometrial cancer incidence, 1978–2013. J Natl Cancer Inst, 2018, vol. 110 (4), pp. 354–361.
3. Morice P., Leary A., Creutzberg C., Abu-Rustum N.D.E. Endometrial cancer. Lancet, 2016, vol. 387 (100231), pp. 1094–1108.
4. Sanderson P.A., Critchley H.O.D., Williams A.R.W., Arends M.J., Saunders P.T.K. New concepts for an old problem: The diagnosis of endometrial hyperplasia. Hum Reprod Update, 2017, vol. 23 (2), pp. 232–254.
5. Kurman R., Carcangiu M., Herrington C.Y.R. World Health Organisation Classification of Tumors of Female Reproductive Organs, 4th edn. Lyon Fr Int Agency Res Cancer Press, 2014.
6. Singh G., Puckett Y. Endometrial Hyperplasia. Stat Pearls Publishing, 2020.
7. Goncharenko V.M., Beniuk V.A., Kalenska O.V. et al. Predictive diagnosis of endometrial hyperplasia and personalized therapeutic strategy in women of fertile age. EPMA J, 2013, vol. 4 (1), p. 24.
8. Reed S.D., Newton K.M., Clinton W.L. et al. Incidence of endometrial hyperplasia. Am. J Obstet Gynecol, 2009, vol. 200 (6), p. 678.
9. Kurman R.J., Norris H.J. Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer, 1982, vol. 49 (12), pp. 2547–2559.
10. Koskas M., Uzan J., Luton D. et al. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: Systematic review and meta-analysis. Fertil Steril., 2014, vol. 101 (3), pp. 785–794.
11. Russo M., Newell J.M., Budurlean L. et al. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. Cancer, 2020, vol. 126 (12), pp. 2775–2783.
12. Lacey J.V. Jr., Sherman M.E., Rush B.B. et al. Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. J Clin Oncol., 2010, vol. 28, pp. 788–792.
13. Doherty M.T., Sanni O.B., Coleman H.G. et al. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: A systematic review and meta-analysis. PLoS One, 2020, vol. 15 (4), p. e0232231.
14. Auclair M.H., Yong P.J., Salvador Set al. Guideline No. 392 — Classification and Management of Endometrial Hyperplasia. J Obstet Gynaecol Can, 2019, vol. 41 (12), pp. 1789–1800
15. Sanderson P.A., Critchley H.O., Williams A.R. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update, 2017, vol. 23, pp. 232–254.
16. Ponomarenko I., Reshetnikov E., Polonikov A. Candidate genes for age at menarche are associated with endometrial hyperplasia. Gene, 2020, 144933.
17. https://www.ncbi.nlm.nih.gov/gene/207
18. Cheng T.H., Thompson D.J., O’Mara T.A. Five endometrial cancer risk loci identified through genome-wide association analysis. Nat Genet., 2016, vol. 48 (6), pp. 667–674.
19. O’Mara T.A., Glubb D.M., Amant F. et al. Identification of nine new susceptibility loci for endometrial cancer. Nat Commun., 2018, vol. 9 (1), pp. 3166.
20. Gabidullina R.I., Nukhbala F.R., Smirnova G.A. et al. Influence of single nucleotide polymorphisms of genes AKT1 (rs2498796) and HEY2 (rs13328928) on the risk of developing endometrial cancer in women of the Republic of Tatarstan. Kazanskiy meditsinskiy zhurnal, 2019, vol. 100, no. 5, pp. 769–773 (in Russ.).